TY - JOUR T1 - Extracellular Microenvironment in Patient-derived Hydrogel Organoids of Prostate Cancer Regulates Therapeutic Response JF - medRxiv DO - 10.1101/2020.05.17.20104349 SP - 2020.05.17.20104349 AU - Matthew J Mosquera AU - Rohan Bareja AU - Jacob Bernheim AU - Muhammad Asad AU - Cynthia Cheung AU - Michael Sigouros AU - Varun Prabhu AU - Joshua E Allen AU - M. Laura Martin AU - Loredana Puca AU - Mark Rubin AU - Himisha Beltran AU - Juan Miguel Mosquera AU - Olivier Elemento AU - Ankur Singh Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/20/2020.05.17.20104349.abstract N2 - Following treatment with androgen receptor (AR) pathway inhibitors, ~20% of prostate cancer patients progress by shedding their dependence on AR. These tumors undergo epigenetic reprogramming turning castration-resistant prostate cancer adenocarcinoma (CRPC-Adeno) into neuroendocrine prostate cancer (CRPC-NEPC). Currently, no targeted therapies are available for CRPC-NEPCs. A major hurdle in the development of new therapies and treatment of CRPC-NEPC is the lack of accurate models to test candidate treatments. Such models would ideally capture components of the tumor microenvironment (TME) factors, which likely regulate the phenotypic, genetic, and epigenetic underpinnings of this aggressive subset. The TME is a complex system comprised not only of malignant prostate cells but also stromal and inflammatory cells and a scaffold of extracellular matrix (ECM). ECM proteins are implicated in the survival and progression of cancer and development of chemoresistance, while are equally integral to the development of prostate cancer organoids. Here, using a combination of patient tumor proteomics and RNA sequencing, we define putative ECM cues that may guide the growth of prostate tumors in patients. Using this molecular information, we developed synthetic hydrogels that recapitulate the tumor ECM. Organoids cultured in the synthetic hydrogel niches demonstrate that ECM subtypes regulate the morphology, transcriptome, and epigenetics hallmarks of CRPC-Adeno and CRPC-NEPC. CRPC-NEPC organoid showed a differential response to small molecule inhibitors of epigenetic repressor EZH2 and Dopamine Receptor D2 (DRD2), the latter being a novel target in CRPC-NEPC when grown in tumor-specific ECM. Finally, in those synthetic ECM niches where drug resistance was observed in CRPC-NEPCs, cellular reprogramming by a synergistic combination of EZH2 inhibitors with DRD2 antagonists inhibited tumor growth. The synthetic platform can provide a more realistic prostate-specific microenvironment and subsequently enable the development of effective targeted therapeutics for prostate cancers.Competing Interest StatementVP and JEA are employees and shareholders of Oncoceutics. Funding StatementThe authors acknowledge financial support from the National Cancer Institute of the US National Institutes of Health (5P50CA211024 awarded to H.B, J.M.M, M.R, M.A, O.E., and A.S.), a US National Science Foundation CAREER award (DMR-1554275 awarded to A.S.), and the Innovative Molecular Analysis Technology program of the US National Cancer Institute (NIH R33-CA212968-01 awarded to A.S.). The authors acknowledge financial support from the NIH Immunoengineering T32 training grant to M.J.M (NIBIB, 1T32EB023860-01A1). Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the funding agency.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRNA sequencing datasets will be made available before peer-reviewed publication. ER -